LAS VEGAS – Translational Software, a vendor of technology that uses genetic data for clinical decision support and precision medicine, has launched at HIMSS16 a drug-drug interaction capability powered by First Databank, a vendor of drug information designed to help improve medication-related decisions and patient outcomes.

Translational Software will be demonstrating the new integrated medication alerting system in the Hearst Health/First Databank exhibit hall booth (#1143) at the HIMSS16 conference in Las Vegas.

[Also: ExtraHop announces new healthcare analytics product]

The company has integrated First Databank Cloud Connector, a web service that delivers First Databank’s drug-drug interaction content, for use with Translational Software’s pharmacogenetic knowledge base and interpretation platform to help clinicians identify and prevent harmful drug interactions and make informed medication decisions for effective patient treatment, the vendor said.

“We are pleased to be working with Translational Software to expand their comprehensive knowledge base to guide precision medicine initiatives for their customers."

Translational Software’s pharmacogenetic portal and knowledge base interprets molecular test results across a variety of medical domains to help physicians deliver personalized care, and the collaboration with First Databank enables Translational Software to integrate raw genetic results data with a single source for both drug-gene and drug-drug information to help clinicians predict potential interactions and adverse drug events when choosing alternative patient therapies, the company said.

Physicians receive a report and color-coded list of all known medications for which dosing should be personalized on the basis of a patient’s genetic test results, coupled with recommended medication alternatives and dosing guidance.

“Through our collaboration with First Databank, we have incorporated the most clinically significant drug-drug interaction alerts available, making our pharmacogenetic knowledge base even more actionable to help minimize the risk of adverse interactions and improve the success of treatment outcomes,” said Don Rule, CEO of Translational Software. “Working with First Databank continues to build on our core mission of helping leading labs and healthcare providers link a patient’s genetic makeup and unique risk factors to specific clinical guidance, all within the clinical workflow.”

Twitter: @SiwickiHealthIT

This story is part of our ongoing coverage of the HIMSS16 conference. Follow our live blog for real-time updates, and visit Destination HIMSS16 for a full rundown of our reporting from the show. For a selection of some of the best social media posts of the show, visit our Trending at #HIMSS16 hub.